immunotherapy

Cantargia: New Data from Two Clinical Studies Strongly Support Nadunolimab Efficacy After Relapse on PD1-Inhibitors

LUND, SE / ACCESSWIRE / September 8, 2024 / Cantargia (STO:CANTA) Cantargia (Cantargia AB; Nasdaq Stockholm:CANTA) today reported data from…

1 year ago

Oncolytics Biotech® to Participate in Fireside Chats at Two Investment Conferences in September

SAN DIEGO and CALGARY, AB, Sept. 6, 2024 /PRNewswire/ -- Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC), a leading clinical-stage company specializing…

1 year ago

Ovation.io and PD Theranostics (PDTx) Complete Merger Creating a Multiomic Data Company Which Owns a Unique Population-Scale Biobank of Disease-Specific Biospecimens

Ovation owns a unique population-scale biobank of consented and linkable disease-specific biospecimens, which includes more than 1.6 million samples from…

1 year ago

Lucius Partners Portfolio Company, PD Theranostics, Completes its Merger with Ovation.io Creating a Multiomic Data Company Which Owns a Unique Population-Scale Biobank of Disease-Specific Biospecimens

Ovation owns a unique population-scale biobank of consented and linkable disease-specific biospecimens, which includes more than 1.6 million samples from over…

1 year ago

Indaptus Therapeutics Reports Encouraging New Safety Data for Decoy20 Clinical Program; Company Expands Enrollment of Patients on Weekly Dosing at Two Different Doses

NEW YORK, Sept. 05, 2024 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (Nasdaq: INDP) (“Indaptus” or the “Company”), a clinical stage…

1 year ago

Lisata Therapeutics’ Certepetide Granted FDA Orphan Drug Designation for the Treatment of Cholangiocarcinoma

BASKING RIDGE, N.J., Sept. 05, 2024 (GLOBE NEWSWIRE) -- Lisata Therapeutics, Inc. (Nasdaq: LSTA) (“Lisata” or the “Company”), a clinical-stage…

1 year ago

Caris Life Sciences to Showcase Research Highlighting the Clinical Value of Comprehensive Molecular Profiling at ESMO 2024

In collaboration with leading cancer centers, research results to be presented from seven studies across a wide range of tumor…

1 year ago

PhaseV to Present at Upcoming Healthcare, Pharma and Technology Events

New Research and Case Studies Demonstrate Effectiveness of Machine Learning-Based Platforms for Adaptive Clinical Trial Design and Analysis BOSTON, Sept.…

1 year ago

Y-mAbs to Participate in Upcoming Investor Conferences in September

NEW YORK, Sept. 03, 2024 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB), a commercial-stage biopharmaceutical…

1 year ago

Galectin Therapeutics to Present at the H.C. Wainwright 26th Annual Global Investment Conference

NORCROSS, Ga., Sept. 03, 2024 (GLOBE NEWSWIRE) -- Galectin Therapeutics, Inc. (NASDAQ: GALT), the leading developer of therapeutics that target…

1 year ago